Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine

Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine (November 2019)

Friday, November 22, 2019 in Phoenix, AZ
Dinner -- JW Marriott Desert Ridge, 5:00 PM MT
Grand Saguaro Ballroom South, Ballroom Level 1


5:00 PM – 5:30 PM  Dinner and Registration

5:30 PM  Welcome and Introduction

5:40 PM  Targeting NTRK Gene Fusions in GBM

6:10 PM  Multiple Receptor TKIs in Recurrent GBM in the Absence of Actionable Targets

6:40 PM  Current Clinical Trials and Unique Small Molecule Targets in GBM

7:10 PM  Panel Discussion and Audience Q&A

7:25 PM  Closing Remarks


Program Director
Tom Mikkelsen, MD, FRCPC

Medical Director, Precision Medicine Program & Clinical Trials
Henry Ford Cancer Institute
Henry Ford Health System
Detroit, Michigan

Manmeet S. Ahluwalia, MD, FACP

Professor, Department of Medicine
Clinic Lerner College of Medicine
Case Western Reserve Universtiy
Dean, Diane Miller Family Endowed Chair in Neuro-Oncology
Director, Brain Metastasis Research Program
Associate Director, Head of Operations
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Neurological Institute of Cleveland Clinic
Cleveland, Ohio

Rimas V. Lukas, MD

Associate Professor of Neurology (Neuro-oncology)
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Goal Statement
The goal of this activity is to improve participant’s competence in integrating new and emerging agents into the treatment of patients with glioblastoma.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with glioblastoma.

Learning Objectives

  • Integrate new targeted therapeutic TKIs into clinical practice for patients with glioblastoma multiforme based on individual patient and tumor characteristics
  • Describe the rationale for targeting NTRK gene fusion in glioblastoma and the effects of NTRK fusions on standard treatment selection
  • Discuss the current and emerging clinical data on promising small molecule TKI therapies for specific targets in the treatment recurrent glioblastoma multiforme
  • Select optimal treatment for patients with recurrent glioblastoma multiforme based on current evidence and molecular markers


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.